Efficacy and safety of fasiglifam (TAK-875), a G protein-coupled receptor 40 agonist, in Japanese patients with type 2 diabetes inadequately controlled by diet and exercise: a randomized, double-blind, placebo-controlled, phase III trial

Kaku K.; Enya K.; Nakaya R.; Ohira T.; Matsuno R.

首页> 外文期刊>Diabetes, obesity & metabolism >Efficacy and safety of fasiglifam (TAK-875), a G protein-coupled receptor 40 agonist, in Japanese patients with type 2 diabetes inadequately controlled by diet and exercise: a randomized, double-blind, placebo-controlled, phase III trial

【24h】

Efficacy and safety of fasiglifam (TAK-875), a G protein-coupled receptor 40 agonist, in Japanese patients with type 2 diabetes inadequately controlled by diet and exercise: a randomized, double-blind, placebo-controlled, phase III trial

机译：在饮食和运动控制不充分的日本2型糖尿病患者中，G蛋白偶联受体40激动剂Fasiglifam（TAK-875）的疗效和安全性：一项随机，双盲，安慰剂对照的III期临床试验

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

Aim: To assess the efficacy and safety of fasiglifam 25 and 50 mg in Japanese patients with type 2 diabetes inadequately controlled by diet and exercise.

机译：目的：评估在饮食和运动控制不充分的日本2型糖尿病患者中，法西格甜25和50 mg的疗效和安全性。

著录项

来源
《Diabetes, obesity & metabolism》 |2015年第7期|共7页
作者
Kaku K.; Enya K.; Nakaya R.; Ohira T.; Matsuno R.;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类内分泌腺疾病及代谢病;
关键词
fasiglifam; GPR40; Japanese patients; TAK-875; type 2 diabetes;

机译：fasiglifam;GPR40;日本患者;TAK-875;2型糖尿病;

相似文献

外文文献
中文文献

1. Efficacy and safety of fasiglifam (TAK-875), a G protein-coupled receptor 40 agonist, in Japanese patients with type 2 diabetes inadequately controlled by diet and exercise: a randomized, double-blind, placebo-controlled, phase III trial [J] . Kaku K., Enya K., Nakaya R., Diabetes, obesity & metabolism . 2015,第7期

机译：在饮食和运动控制不充分的日本2型糖尿病患者中，G蛋白偶联受体40激动剂Fasiglifam（TAK-875）的疗效和安全性：一项随机，双盲，安慰剂对照的III期临床试验
2. Long-term safety and efficacy of fasiglifam (TAK-875), a G-protein-coupled receptor 40 agonist, as monotherapy and combination therapy in Japanese patients with type 2 diabetes: a 52-week open-label phase III study [J] . Kaku K., Enya K., Nakaya R., Diabetes, obesity & metabolism . 2016,第9期

机译：日本2型糖尿病患者单药和联合用药Fasiglifam（TAK-875）（一种G蛋白偶联受体40激动剂）的长期安全性和有效性：一项为期52周的III期开放性研究
3. A randomized, double-blind, placebo-controlled, phase II clinical trial to investigate the efficacy and safety of oral DA-1229 in patients with type 2 diabetes mellitus who have inadequate glycaemic control with diet and exercise [J] . DepartmentofInternalMedicineAsanMedicalCenter, DepartmentofInternalMedicineKangbukSamsungMedicalCenter, DepartmentofInternalMedicineGangdongKyungheeUniversityHospitalSeoul, Diabetes/metabolism research and reviews . 2015,第3期

机译：一项随机，双盲，安慰剂对照的II期临床试验，旨在研究口服DA-1229在饮食和运动对血糖控制不足的2型糖尿病患者中的有效性和安全性
4. A DOUBLE-BLIND RANDOMIZED PLACEBO-CONTROLLED CLINICAL TRIAL TO INVESTIGATE THE EFFICACY OF TIAMULIN IN THE CONTROL OF PORCINE PROLIFERATIVE ENTEROPATHY (PPE) AND PORCINE COLONIC SPIROCHAETOSIS (PCS) UNDER FIELD CONDITIONS [C] . J. Haugegaard, K. Moller, T.K. Jensen, Congress of the International Pig Veterinary Society . 2000

机译：一种双盲随机安慰剂对照临床试验，探讨硫霉素在野生植物中猪增殖肠病（PPE）和猪结肠螺旋肌肤症（PCS）的疗效
5. A Phase II, Randomized, Double-Blind, Placebo-Controlled Trial of Fish Oil (Eicosapentaenoic Acid and Docosahexaenoic Acid) on Lung and Systemic Inflammation in Patients with Acute Lung Injury. [D] . Stapleton, Renee Doney. 2010

机译：鱼油（二十碳五烯酸和二十二碳六烯酸）对急性肺损伤患者的肺和全身炎症的II期，随机，双盲，安慰剂对照试验。
6. Efficacy and safety of fasiglifam (TAK-875) a G protein-coupled receptor 40 agonist in Japanese patients with type 2 diabetes inadequately controlled by diet and exercise: a randomized double-blind placebo-controlled phase III trial [O] . K Kaku, K Enya, R Nakaya, -1

机译：在饮食和运动控制不充分的日本2型糖尿病患者中G蛋白偶联受体40激动剂Fasiglifam（TAK-875）的疗效和安全性：一项随机双盲安慰剂对照的III期临床试验
7. Efficacy and safety of the G protein-coupled receptor 119 agonist DS-8500a in Japanese type 2 diabetes mellitus patients with inadequate glycemic control on sitagliptin: A phase 2 randomized placebo-controlled study [O] . Yasuo Terauchi, Yuichiro Yamada, Hirotaka Watada, 2018

机译：日本型2型糖尿病患者的G蛋白偶联受体119激动剂DS-8500A的疗效和安全性具有不足的血糖对SITAGLIPTIN的血糖控制：A相随机安慰剂对照研究

Efficacy and safety of fasiglifam (TAK-875), a G protein-coupled receptor 40 agonist, in Japanese patients with type 2 diabetes inadequately controlled by diet and exercise: a randomized, double-blind, placebo-controlled, phase III trial

摘要

著录项

相似文献

相关主题

期刊订阅